Stocks and Investing Stocks and Investing
Thu, October 21, 2021

Matthew Harrison Maintained (BIIB) at Buy with Decreased Target to $440 on, Oct 21st, 2021


Published on 2024-10-27 18:15:25 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $447 to $440 on, Oct 21st, 2021.

Matthew has made no other calls on BIIB in the last 4 months.



There are 7 other peers that have a rating on BIIB. Out of the 7 peers that are also analyzing BIIB, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Alethia Young of "Cantor Fitzgerald" Maintained at Hold with Decreased Target to $327 on, Friday, October 15th, 2021
  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $290 on, Friday, October 8th, 2021
  • Salim Syed of "Mizuho" Maintained at Hold with Increased Target to $300 on, Monday, August 2nd, 2021


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $344 on, Friday, October 15th, 2021
  • Michael Yee of "Jefferies" Maintained at Strong Buy with Decreased Target to $400 on, Friday, October 8th, 2021
  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $442 on, Thursday, September 16th, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $423 on, Tuesday, July 27th, 2021

Contributing Sources